Medical weight loss is care from a licensed prescriber for excess weight that can include FDA-approved GLP-1 drugs plus diet and activity changes.
Low obesity, but diabetes is not low
CDC PLACES puts San Francisco adult obesity at 17.2%, yet diagnosed diabetes at 10.2% [3]. That gap is a reminder that GLP-1 decisions here are often about blood sugar as much as weight. Ozempic and Mounjaro are labeled for type 2 diabetes [6][7]; Wegovy and Zepbound are labeled for weight [8][9].
Sponsored placement: open.
One local practice can be featured here. This is a paid, labeled placement and never an endorsement.
Feature your practice in San Francisco Bay Area, from $300 a month.
A sponsor paid for this labeled spot. We do not endorse it.
Paying for it in the Bay Area
Medi-Cal ended adult weight-loss GLP-1 coverage on Jan 1 2026, though members under 21 and non-weight uses can still be covered [2]. With a median household income of $140,970 [4], many residents have employer plans, but Lilly cites an IFEBP survey finding about half of employer-insured Americans lack obesity drug coverage [10].
| Product | Monthly | Source |
|---|---|---|
| Wegovy pen (semaglutide) | $349 | [1] |
| Wegovy pill (semaglutide) | $149 to $299 | [1] |
| Zepbound (tirzepatide) | $299 to $449 | [11] |
| Foundayo (orforglipron) | $149 to $299 | [12] |
Finding a prescriber
We were not able to confirm specific Bay Area hospital weight programs for this guide, so we do not list any. Primary care, endocrinology and online programs all prescribe. Check licenses on the Medical Board of California site [5]. Avoid sellers that describe a compounded drug as the same as Wegovy; FDA has warned dozens of telehealth companies over such claims [13].
Safety
Stop the drug and get help for severe stomach pain that does not go away. Do not use semaglutide with a family history of medullary thyroid carcinoma or MEN 2. Stop Wegovy at least 2 months before a planned pregnancy [8]. Call 911 for emergencies.
Nearby: San Jose, Sacramento, Los Angeles, Seattle. Guides: weight loss, find a clinic, semaglutide.
Questions people ask
How much is semaglutide in San Francisco?
Manufacturer self-pay is $349 a month for the Wegovy pen and $149 to $299 for the Wegovy pill, as of Oct 17 2026 [1].
Does Medi-Cal cover Wegovy in San Francisco?
Not for adult weight loss since Jan 1 2026. Members under 21 keep coverage, and non-weight uses may be covered when medically necessary [2].
What is the obesity rate in San Francisco?
CDC PLACES estimates 17.2% of San Francisco adults had obesity in 2023, with 10.2% reporting diagnosed diabetes [3].
Do employers in the Bay Area cover GLP-1s?
It depends on the plan. Lilly, citing an IFEBP survey, says about half of Americans with employer insurance lack coverage for obesity medications [10].
How do I check a San Francisco prescriber?
Search the prescriber's name on the Medical Board of California website before your first visit [5].
Sources
14 cited
- Wegovy self-pay offer. Novo Nordisk (NovoCare Pharmacy), Oct 17, 2026.
- California Medicaid ends coverage of GLP-1 weight loss drugs. KFF Health News, Jan 9, 2026.
- PLACES: County Data, San Francisco (2025 release, BRFSS 2023). CDC, 2023.
- QuickFacts: San Francisco city, California. U.S. Census Bureau, 2025.
- Medical Board of California. State of California, Oct 17, 2026.
- Ozempic label. DailyMed, National Library of Medicine, May 2026.
- Mounjaro label. DailyMed, National Library of Medicine, Aug 2026.
- Wegovy label (injection and tablets). DailyMed, National Library of Medicine, Jun 2026.
- Zepbound label. DailyMed, National Library of Medicine, Aug 2026.
- Foundayo now available (press release citing IFEBP survey). Eli Lilly and Company, Apr 9, 2026.
- Zepbound self-pay pricing. Eli Lilly and Company (LillyDirect), Oct 17, 2026.
- Foundayo self-pay pricing. Eli Lilly and Company (LillyDirect), Oct 17, 2026.
- FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. U.S. Food and Drug Administration, Mar 3, 2026.
- FDA's concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, Oct 1, 2026.
This page is general information, not medical advice. Talk with a licensed clinician about your own care.